Most Read

Under the deal, the US-based biotech company has granted an exclusive, worldwide, royalty-bearing license to Takeda Pharmaceutical pertaining to cell and non-cell therapy products that modulate targets identified

VIR-7832, a neutralising Covid-19 antibody, attaches to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1. According to GSK, the preclinical data suggests that VIR-7832 has two distinguishing

According to the India-based pharma company, the Sputnik V vaccine has been recommended by an independent data and safety monitoring board (DSMB) to advance to a phase 3

As per terms of the deal, Kymab will secure an upfront payment of up to $1.1bn from Sanofi. Kymab is also eligible to secure up to $350m based

The in vitro study, which was held by Pfizer and the University of Texas Medical Branch (UTMB), demonstrated that the antibodies from people subjected to the vaccine could

The company has pooled funds in a financing round co-led by new investors Rock Springs Capital and Foresite Capital. Other new investors consist of T. Rowe Price, Wellington

The phase III randomised, double-blind, placebo-controlled, two-arm, parallel-group and multi-centre study will assess safety, tolerability and clinical benefit of the company’s human recombinant alkaline phosphatase to treat patients

As per terms of the deal, Bayer will extend its support for further development, supply and crucial territory operations of CureVac´s Covid-19 vaccine candidate. By the end of

The conditional marketing authorisation is based on the recommendation of the European Medicines Agency (EMA) for use of the Covid-19 Vaccine Moderna for active immunisation to prevent Covid-19